---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049796"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:38:53.343619+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma closes $7.5M private placement for GTX-104 development

## Summary
- Closed private placement on Sept 25, 2023: 1.95M common shares at $1.848 each, pre-funded warrants for 2.11M shares, and common warrants for 2.54M shares at $3.003 exercise.
- Gross proceeds ~$7.5M, net ~$7.3M after fees; related parties (Shore Pharma, SS Pharma) participated.
- Proceeds intended for GTX-104 Phase 3 trial, pre-commercial planning, working capital, and general corporate purposes.
- Common warrants expire on the earlier of 60 days after FDA NDA acceptance for GTX-104 or 5 years from issuance.
- Company to file resale registration statement within 30 days; failure may trigger liquidated damages.

## SEC filing metadata
- accession: 0000950170-23-049796
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/0000950170-23-049796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-20230924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049796
- JSON: https://secwatch.observer/filing/0000950170-23-049796.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049796.txt

## Key facts
- Material Agreements
  Grace Therapeutics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $7.3 million (effective 2023-09-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $7.3 million
  - Effective: 2023-09-24
  source text: On September 24, 2023, Acasti Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors in connection with a private placement offering of the Company's securities (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/0000950170-23-049796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.